CN1634193A - Medicine for treating constipation, halitosis and gum swelling - Google Patents
Medicine for treating constipation, halitosis and gum swelling Download PDFInfo
- Publication number
- CN1634193A CN1634193A CN 200310121022 CN200310121022A CN1634193A CN 1634193 A CN1634193 A CN 1634193A CN 200310121022 CN200310121022 CN 200310121022 CN 200310121022 A CN200310121022 A CN 200310121022A CN 1634193 A CN1634193 A CN 1634193A
- Authority
- CN
- China
- Prior art keywords
- group
- medicine
- test
- halitosis
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 38
- 206010010774 Constipation Diseases 0.000 title claims abstract description 28
- 206010006326 Breath odour Diseases 0.000 title claims abstract description 20
- 208000032139 Halitosis Diseases 0.000 title claims abstract description 20
- 206010018291 Gingival swelling Diseases 0.000 title claims abstract description 17
- 229940079593 drug Drugs 0.000 title description 7
- 230000036407 pain Effects 0.000 claims description 18
- 206010018286 Gingival pain Diseases 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 239000002994 raw material Substances 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 5
- 239000000706 filtrate Substances 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 239000000047 product Substances 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000010135 fructus aurantii immaturus Substances 0.000 claims description 2
- 238000003672 processing method Methods 0.000 claims description 2
- 238000010298 pulverizing process Methods 0.000 claims description 2
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 abstract 1
- 241000213006 Angelica dahurica Species 0.000 abstract 1
- 235000003097 Artemisia absinthium Nutrition 0.000 abstract 1
- 240000001851 Artemisia dracunculus Species 0.000 abstract 1
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 abstract 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 abstract 1
- 244000183685 Citrus aurantium Species 0.000 abstract 1
- 235000007716 Citrus aurantium Nutrition 0.000 abstract 1
- 241000758993 Equisetidae Species 0.000 abstract 1
- 241000501743 Gentiana macrophylla Species 0.000 abstract 1
- 244000170916 Paeonia officinalis Species 0.000 abstract 1
- 235000006484 Paeonia officinalis Nutrition 0.000 abstract 1
- 244000299790 Rheum rhabarbarum Species 0.000 abstract 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 abstract 1
- 239000001138 artemisia absinthium Substances 0.000 abstract 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 48
- 239000002775 capsule Substances 0.000 description 32
- 230000000694 effects Effects 0.000 description 29
- 241000699670 Mus sp. Species 0.000 description 20
- 238000000034 method Methods 0.000 description 16
- 241000699666 Mus <mouse, genus> Species 0.000 description 14
- 230000013872 defecation Effects 0.000 description 14
- 241000700159 Rattus Species 0.000 description 13
- 201000010099 disease Diseases 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 210000001072 colon Anatomy 0.000 description 10
- 239000000976 ink Substances 0.000 description 10
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 7
- 206010030113 Oedema Diseases 0.000 description 7
- 230000000202 analgesic effect Effects 0.000 description 7
- 210000002683 foot Anatomy 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 230000033001 locomotion Effects 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 235000010418 carrageenan Nutrition 0.000 description 6
- 229920001525 carrageenan Polymers 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- AEQDJSLRWYMAQI-KRWDZBQOSA-N tetrahydropalmatine Chemical compound C1CN2CC(C(=C(OC)C=C3)OC)=C3C[C@H]2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-KRWDZBQOSA-N 0.000 description 6
- 208000000114 Pain Threshold Diseases 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 238000009395 breeding Methods 0.000 description 5
- 230000001488 breeding effect Effects 0.000 description 5
- 230000003907 kidney function Effects 0.000 description 5
- 230000037040 pain threshold Effects 0.000 description 5
- 229960001138 acetylsalicylic acid Drugs 0.000 description 4
- 210000003608 fece Anatomy 0.000 description 4
- 210000001809 melena Anatomy 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 210000000813 small intestine Anatomy 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 241001529739 Prunella <angiosperm> Species 0.000 description 3
- 208000005946 Xerostomia Diseases 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 208000019790 abdominal distention Diseases 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 238000009534 blood test Methods 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 229940113118 carrageenan Drugs 0.000 description 3
- 239000000679 carrageenan Substances 0.000 description 3
- 239000003610 charcoal Substances 0.000 description 3
- 238000003748 differential diagnosis Methods 0.000 description 3
- 206010013781 dry mouth Diseases 0.000 description 3
- 210000005069 ears Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 239000012362 glacial acetic acid Substances 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 230000009545 invasion Effects 0.000 description 3
- 231100000957 no side effect Toxicity 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 3
- 206010000087 Abdominal pain upper Diseases 0.000 description 2
- 240000006409 Acacia auriculiformis Species 0.000 description 2
- 206010002153 Anal fissure Diseases 0.000 description 2
- 208000016583 Anus disease Diseases 0.000 description 2
- 208000009531 Fissure in Ano Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010030302 Oliguria Diseases 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000009931 harmful effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000035861 hematochezia Diseases 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 210000000713 mesentery Anatomy 0.000 description 2
- 238000007427 paired t-test Methods 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 210000001187 pylorus Anatomy 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229930189907 rotundine Natural products 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000252983 Caecum Species 0.000 description 1
- 208000001387 Causalgia Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- 241000594182 Sarcophaga sigma Species 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 210000000544 articulatio talocruralis Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 238000009535 clinical urine test Methods 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 208000014439 complex regional pain syndrome type 2 Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000004195 gingiva Anatomy 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- 201000008267 intestinal tuberculosis Diseases 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000009592 kidney function test Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 208000014081 polyp of colon Diseases 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides a medicine for treating constipation, halitosis and gum swelling, which is prepared from rhubarb horsetails, immature bitter orange, oriental wormwood, Chinese angelica root, bark of peony root, gentiana macrophylla pall.
Description
Technical field
The present invention relates to a kind of Chinese medicine preparation, especially a kind of pharmaceutical preparation for the treatment of constipation, halitosis, gingival swelling and pain.
Background technology
The crowd of, maror rich for happiness food usually is often because of heat-transformation is lit a fire, pathogenic heat enemy intrusion or invasion causes the long-pending heat of gastrointestinal, so acid regurgitation eructating foul odor again, just consume the bright liquid in Tianjin year in and year out, pure and impure two gas imbalance, burning pain in the epigastrium, foul smell is non-return, diseases such as halitosis, constipation, gingival swelling and pain occur.Not only be difficult to people contacts, and the hardship of slight illness extremely.At present the medicine of treatment constipation or gingival swelling and pain is more, and effect differs, but it is rare to take into account the medicine of treatment halitosis simultaneously.For this reason, be necessary to develop and develop and can remove patient's slight illness and worried, and Chinese medicine preparation evident in efficacy, that have no side effect, to satisfy people's needs.
Summary of the invention
Purpose of the present invention is exactly to provide a kind of treatment stomach-fire to contain partially in order to overcome the deficiency of above-mentioned prior art, stops the Chinese traditional compound medicine of the herbal mixture treatment constipation of the halitosis due to the adverse flow of turbid QI, constipation, gingival swelling and pain, halitosis, gingival swelling and pain in the pathogenic heat.
Research worker of the present invention is through research for many years and in conjunction with China's Chinese medicine theory, think that mostly the reason that causes " halitosis " is to have a liking at ordinary times the pungent rich food of food, for a long time long-pending heat-transformation light a fire or feelings will unhappy, pathogenic heat enemy intrusion or invasion, in the food stagnation stomach, the sour belch, stomach-fire is followed row and is gone up smoked, the bright liquid in consumption Tianjin, very then gingival swelling and pain, the stain of suppurating are rotted, so see halitosis.So should be on Therapeutic Method with dispelling wind and heat pathogens, clearing away heat and cooling blood is eliminated the fiery dysphoria with smothery sensation of volt, the peace gastric qi, drive cut off the water, the turbid descending gas is its basic norm, make it to reach brokenly foul smell, the circulation of qi promoting removing food stagnancy, purging heat to relax the bowels, QI invigorating is made light of one's life by commiting suicide, cleanse gastrointestinal, push away Chen Zhixin, peace and the five internal organs, the turbid descending stagnant purpose that disappears.
According to mentioned above principle, the present invention realizes by following technical proposal: a kind of medicine for the treatment of constipation, halitosis, gingival swelling and pain is characterized in that being made by the raw material of following weight portion:
Radix Et Rhizoma Rhei 100-120 part Fructus Aurantii Immaturus 100-110 part
Herba Artemisiae Scopariae 100-120 part Radix Angelicae Sinensis 70-85 part
Cortex Moutan 50-60 part Radix Gentianae Macrophyllae 100-120 part
Herba Equiseti Hiemalis 100-120 part Spica Prunellae 100-120 part.
The present invention adopts processing method of the prior art to make, and after soon raw material was cleaned, dried, powder became fine powder, mix homogeneously.Perhaps raw material is decocted with water for several times, collecting decoction filters, and filtrate is condensed into thick paste, and dry, pulverizing makes the acceptable preparation product.
Allocate medical accessory again into prescription of the present invention and promptly can be made into pharmaceutically acceptable any dosage form.
The present invention has following advantage and effect: this medicine has circulation of qi promoting removing food stagnancy, purging heat to relax the bowels, removing damp-heat, dispelling wind and heat pathogens, effects such as clearing away heat and cooling blood can be removed in the stomach burning hot, the stomach causalgia, to treatment pathogenic heat enemy intrusion or invasion, in the food stagnation stomach, stomach-fire is driven in the wrong direction for going up and is smoked, halitosis, constipation, gingival swelling and pain due to the bright liquid in consumption Tianjin have reliable curative effect, cure rate reaches more than 80%, and the men and women all can use, and has no side effect.
The specific embodiment
Embodiment 1
Get the raw materials ready by following prescription:
Radix Et Rhizoma Rhei 100 gram Fructus Aurantii Immaturuss 110 grams
Herba Artemisiae Scopariae 100 gram Radix Angelicae Sinensis 85 grams
Cortex Moutan 50 gram Radix Gentianae Macrophyllae 120 grams
Herba Equiseti Hiemalis's 100 gram Spica Prunellaes 120 grams.
Make with following method: Radix Et Rhizoma Rhei, Cortex Moutan, Radix Angelicae Sinensis are ground into fine powder, stand-by; All the other crude drugs were soaked 4-8 hour, decocted 2-4 time, each 1-2 hour, extract decoction liquor, merge each time extracting solution, to filter, filtrate is concentrated into the thick paste that relative density is 1.30 (50 ℃); With above-mentioned fine powder and thick paste mixing, drying, pulverize, sieve, incapsulate 1000 capsules.
Embodiment 2
Adopt the method identical, make 1000 tablets of tablets by following prescription with embodiment 1:
Radix Et Rhizoma Rhei 120 gram Fructus Aurantii Immaturuss 100 grams
Herba Artemisiae Scopariae 120 gram Radix Angelicae Sinensis 70 grams
Cortex Moutan 60 gram Radix Gentianae Macrophyllae 100 grams
Herba Equiseti Hiemalis's 120 gram Spica Prunellaes 100 grams.
Embodiment 3
Adopt method and the existing electuary preparation method identical, make 1000 bag mouth by following prescription and obey electuary with embodiment 1:
Radix Et Rhizoma Rhei 110 gram Fructus Aurantii Immaturuss 105 grams
Herba Artemisiae Scopariae 110 gram Radix Angelicae Sinensis 78 grams
Cortex Moutan 55 gram Radix Gentianae Macrophyllae 110 grams
Herba Equiseti Hiemalis's 110 gram Spica Prunellaes 110 grams.
Pharmacodynamic test of active extract result of the present invention is as follows:
Experiment material
1, medicine: the present invention's capsule, specification: the 0.3g/ grain is equivalent to crude drug 0.725g; Commercial MARENJIAONANG, aspirin, rotundine sheet, dimethylbenzene, glacial acetic acid (analytical pure); The carrageenin that U.S. SIGMA company produces.
2, animal: SD rat, level; ICR mice: level.
3, instrument: the BP310S electronic balance, YSD-4 pharmacology, Physiological Experiment are used instrument more, GJ-8402 hot plate dolorimeter, Mus foot volume determination device, the too suitable board stopwatch of PC9730 type, operating theater instruments, laboratory special uses such as timing clock.
Method and result
1, to the influence of rat colon movement
Get half and half, 50 of qualified SD rat male and female, normal breeding observing is 3 days before the test, give the 1g/kg of rats by intraperitoneal injection 25%, cut off the hair at abdomen middle part after the anesthesia, preserved skin sterilization tailing edge ventrimeson is done 5 to 6cm long longitudinal cuts, opens abdomen, the plastic tube of internal diameter 1mm is inserted colon 1cm by ileocecus, ligation is fixed, and plastic catheter is drawn from the back by muscle skin, in order to administration, abdominal incision is sewed up, and the postoperative fasting is supplied water.The 2nd day random packet of postoperative, if matched group (N.S) MARENJIAONANG group (0.2g/kg) capsule height of the present invention (0.8g/kg), in (0.48g/kg) low (0.16g/kg), administration volume 5ml/kg, above-mentioned medicinal liquid all contains 10% prepared Chinese ink, medicinal liquid is by plastic catheter timing immediately after colonic injects, the administration animal head of fiercelying attack after 10 minutes is put to death, open abdomen immediately, with eye scissors colon is cut by anus to caecum end separation, the careful mesentery that separates is put straight colon on moistening little plank, measures colon total length and prepared Chinese ink advance distance with ruler, and calculate prepared Chinese ink propelling percentage rate, the results are shown in Table 1.
Result of the test shows, capsule of the present invention and MARENJIAONANG all can obviously be accelerated the rat colon movement, compares P＜0.01 with the NS group, and capsule of the present invention increases the effect enhancing with dosage.
Table 1 capsule of the present invention to the influence (prepared Chinese ink method) of rat colon movement (n=10)
Colon length overall prepared Chinese ink advance distance
Group dosage (g/kg)
Propelling rate (%)
(cm) (cm)
NS equal-volume 14.33 ± 1.07 5.18 ± 0.78 36.15
MARENJIAONANG 0.2 14.36 ± 0.95 8.52 ± 1.35
*59.33
The present invention low 0.16 14.01 ± 1.14 7.29 ± 1.24
*52.03
In 0.48 13.28 ± 1.29 8.12 ± 0.96
*61.14
High by 0.8 13.22 ± 1.44 8.93 ± 1.13
*67.55
Annotate: compare with the NS group
*P＜0.01
2, to the influence of mice defecation time and quantity (charcoal end method)
Get 50 of qualified ICR mices, male and female half and half, fasting water supply 12h (diarrhoea person's rejecting) is divided into 5 groups at random, be matched group (NS), MARENJIAONANG group (0.3g/kg), (0.6g/gk) high (1.0g/kg) in the capsule of the present invention low (0.2g/gk), by group ig administration respectively, the ig volume is 0.4ml/10g, all contains charcoal end 0.1g/ml, timing immediately behind the ig, each Mus places the separation carton that is covered with filter paper respectively, observes the time of mice row melena one by one, the feces character, row's melena number the results are shown in Table 2 in the 6h.Table
2 capsules of the present invention are to influence (the charcoal end method) n=10 of mice defecation time and quantity
Row's melena in the dosage row melena time 6h
The group character
(g/kg) (min) count (grain)
NS equal-volume 110.5 ± 12.8 12.0 ± 2.0 are shaped
MARENJIAONANG
0.3 84.9 ± 7.4
*22.5 ± 3.3
*Rare soft
The present invention is low
0.2 96.5 ± 8.1
*18.2 ± 3.0
*Rare soft
In 0.6 92.7 ± 9.5
*18.6 ± 3.3
*Rare soft
High by 1.0 80.17 ± 10.0
*24.4 ± 3.2
*Rare soft
Annotate: compare with NS
*P＜0.01
Result of the test shows that capsule of the present invention and MARENJIAONANG all can obviously shorten the mice defecation time and increase mice defecation quantity, make the feces character thinning soft, and capsule of the present invention strengthens with dosage increase effect.
3, the influence (prepared Chinese ink method) that mouse small intestine is moved
Get 50 of qualified ICR mices, male and female half and half, normal breeding observing is after 3 days, and fasting water supply 12h is divided into 5 groups at random, every group 10, matched group (NS), MARENJIAONANG group (0.3g/kg) capsule of the present invention low (0.2g/kg), in (0.6g/kg), high (1.0g/kg), ig volume (0.4ml/10g), all contain 10% prepared Chinese ink, clock immediately behind the ig respectively by above-mentioned group, 30min behind the medicine takes off the shin vertebra and puts to death animal, open the abdominal cavity and separate mesentery gently, the small intestinal that the portion of educating is gone back in pylorus to lower end, clip upper end places on the pallet, and the shop is straight gently, measure small intestinal total length and pylorus to the distance in prepared Chinese ink forward position, the results are shown in Table 3.
Table 3 capsule of the present invention to the influence (prepared Chinese ink method) of mouse small intestine motion (n=10)
Dosage small intestinal total length prepared Chinese ink advances apart from the propelling rate
Group
(g/kg) (cm) (%) from (cm)
NS equal-volume 43.3 ± 1.8 22.0 ± 1.30 49.6 ± 1.8
MARENJIAONANG 0.3 44.9 ± 1.9 25.7 ± 1.1
*57.4 ± 3.0
*
The present invention low 0.2 45.1 ± 1.8 26.8 ± 1.8
*59.5 ± 3.7
*
In 0.6 46.0 ± 1.5 26.4 ± 1.6
*57.5 ± 4.1
*
High by 1.0 45.6 ± 1.6 27.5 ± 1.3
*60.4 ± 1.5
*
Annotate: compare with NS
*P＜0.01
Result of the test shows, MARENJIAONANG and capsule of the present invention all can obviously strengthen the mouse small intestine motion, and each is organized with NS and organizes relatively P＜0.01, and capsule of the present invention increases the effect enhancing with dosage.
4, the influence of rat paw edema due to the on Carrageenan.
Get qualified SD rat, male, body weight 150～190g, normal breeding observing 3 days, be divided into 5 groups at random, every group 10, matched group (NS), aspirin group (0.5g/kg), capsule of the present invention low (0.16g/kg), in (0.48g/kg), high (0.8g/kg) dosage group, respectively by above-mentioned group ig administration 3 days, 1h does not cause inflammation (0.1ml/ is only) with 1% carrageenin in the right back sufficient plantar subcutaneous injection of each Mus after time administration, with Mus foot volume determination device measure respectively each Mus cause scorching before and cause the right back sufficient sole of the foot volumetric values (use picric acid at each Mus ankle joint marking, this line is equal with liquid level during measurement) of scorching back 4 time periods, and calculate swelling rate and suppression ratio, the results are shown in Table 4.
Result of the test shows, after capsule ig of the present invention gives rat, can significantly suppress rat paw edema due to the carrageenin, and be the dose-effect dependency.
5, the influence of xylol induced mice auricle edema.
Get 50 of qualified ICR mices, male, body weight 25～30g, normal breeding observing 3 days is divided into 5 groups at random, and 10 every group, matched group (N.S) aspirin group (0.5g/gk), capsule of the present invention
The influence (n=10) of rat paw edema due to the table 4 capsule on Carrageenan of the present invention
Group causes scorching back swelling degree (ml X ± S) (%)
Dosage
Other 1h 3h 4h 6h
Deng body
NS 0.44±0.19 0.65±0.23 0.75±0.24 0.55±0.21
Long-pending
A Si 0.15 ± 0.08
*0.22 ± 0.08
*0.27 ± 0.06
*0.17 ± 0.08
*
0.5
Woods (68.3) (68.5) (66.5) (71.3)
This 0.22 ± 0.06
*0.28 ± 0.08
*0.32 ± 0.08
*0.16 ± 0.06
*
0.16
Bright low (57.2) (63.1) (63.4) (75.2)
0.21±0.09
**?0.31±0.12
**?0.37±0.11
**?0.27±0.09
**
0.48
In
(54.8) (54.8) (53.3) (53.5)
0.19±0.08
**?0.28±0.15
**?0.35±0.15
**?0.20±0.12
**
0.8
High
(60.3) (60.4) (57.0) (65.5)
Annotate: compare with NS
*P＜0.01
Low (0.2g/kg), in (0.6g/kg), high (1.0g/kg), give anti-property ig administration 3 days respectively by above-mentioned group, the ig volume is 0.4ml/10g, 1h after the not inferior administration, with 100% dimethylbenzene (0.05ml/ only), wipe outward fully to contact and cause inflammation in each Mus auris dextra two sides, take off cervical vertebra behind the 15min and put to death animal, two ears about taking off, with diameter 8mm card punch each Mus two ear is downcut with the position homalographic, use scales/electronic balance weighing immediately, heavily deducting left ear method of double differences value with auris dextra is the swelling degree, and calculate suppression ratio, the results are shown in Table 5.
The influence (n=10) of table 5 capsule xylol of the present invention induced mice auricle edema
Group dosage (g/kg) swelling degree (mg) suppression ratio (%)
NS equal-volume 9.7 ± 2.1---
Aspirin 0.5 5.2 ± 1.7
*47.9
The present invention low 0.2 7.2 ± 0.9
*35.1
In 0.6 7.3 ± 1.3
*31.9
High by 1.0 6.8 ± 1.6
*36.6
Annotate: compare with NS
*P＜0.01
6, analgesic test (hot plate method)
Get qualified female ICR mice, normal breeding observing 3 days is measured each Mus pain threshold (licking the sufficient time) with hot plate dolorimeter (55 ± 0.5 ℃ of temperature), and is all less than 5 seconds with all give it up greater than 30 seconds persons.Screen 50 of qualified animals, be divided into 5 groups at random, matched group (NS), rotundine group (20mg/kg), capsule of the present invention low (0.2g/kg), in (0.6g/kg), high (1.0g/kg).Each treated animal is measured twice of pain threshold respectively before medication, each 1h at interval, getting twice pain threshold mean is the preceding threshold of pain of administration (S), behind the 1h, by group ig administration respectively, timing immediately, 15min after the mensuration administration, 30min, the pain threshold of 60min3 time period, make paired t-test behind the medicine prodrug on the same group, the results are shown in Table 6.
Table 6 capsule of the present invention is to analgesic activity (hot plate method) n=10 of mice
Pain threshold behind the medicine of the preceding threshold of pain of medicine
Group dosage
(S) 15min 30min 60min
NS equal-volume 18.8 ± 2.0 18.7 ± 2.3 19.9 ± 2.1 19.7 ± 1.9
Rotundine 20mg/kg 19.5 ± 2.6 27.4 ± 4.0
*25.9 ± 3.0
*24.3 ± 2.6
*
The low 0.2g/kg 18.8 of invention ± 2.3 26.8 ± 3.0
*27.1 ± 2.0
*26.8 ± 2.7
*
Middle 0.6g/kg 19.9 ± 2.3 27.8 ± 3.3
*28.5 ± 3.6
*28.4 ± 3.1
*
High 1.0g/kg 19.7 ± 2.3 27.7 ± 3.5
*28.2 ± 3.6
*28.0 ± 3.1
*
Annotate: paired t-test, with comparison before the administration
*P＜0.01
Result of the test shows that capsule senior middle school's low dose group of the present invention and rotundine group all have significant analgesia role.
7, to the analgesic test (writhing method) of mice
Get 50 of qualified ICR mices, male and female half and half, body weight 20～24g, be divided into 5 groups at random, matched group (NS), aspirin (0.2g/gk), capsule of the present invention low (0.2g/kg), in (0.6g/kg), high (1.0g/kg), each treated animal is by above-mentioned dosage ig administration, 30min behind the medicine, turn round the body number of times in each Mus lumbar injection 0.5% glacial acetic acid (0.2ml/ only), immediate record 30 minutes, the results are shown in Table 7.
Table 7 capsule of the present invention is to analgesic activity (writhing method) n=10 of mice
Group dosage (g/kg) is turned round the body number of times
NS equal-volume 43.5 ± 7.4
Aspirin 0.2 22.3 ± 7.0
*
The present invention low 0.2 30.0 ± 6.5
*
In 0.6 24.7 ± 5.3
*
High by 1.0 23.7 ± 7.2
*
Annotate: compare with matched group
*P＜0.01
Result of the test shows, three dosage groups of capsule of the present invention and aspirin group all can significantly suppress mice and turn round the body number of times because of what the lumbar injection glacial acetic acid caused, learn by statistics and handle P＜0.01, illustrate that capsule of the present invention has significant analgesic activity, and be the dose-effect dependency.
Brief summary
The present invention has rushes down turbid relieving constipation, and the effect of heat clearing away toxin expelling dehumidifying clinically is used for the treatment of diseases such as constipation, halitosis, gingival swelling and pain.Function in conjunction with this medicine cures mainly, the spy has carried out the intestinal function test, the relieving constipation test, antiinflammatory test and analgesic test, the result shows, this medicine can obviously be accelerated rat colon movement function, can obviously shorten the mice defecation time and increase mice defecation quantity, make feces thinning soft, can obviously strengthen mouse small intestine motion, rat paw edema and xylol induced mice auricle edema all have obvious inhibitory action due to this product on Carrageenan, present good antiinflammatory action, and significant analgesic activity is arranged, be the dose-effect dependency in the experiment.
The present invention is through clinical trial, and its result is as follows:
One, test objective
Test the curative effect and the clinical drug safety of the capsule for treating constipation of the present invention of further objective evaluation by this.And observation has no adverse reaction the subsidiary treatment accompanied symptoms of observing: the curative effect of halitosis, gingival swelling and pain.
Two, physical data
Constipation (functional constipation card) patient 200 people that select 18-65 year from Yunnan Province institute of traditional Chinese medicine, the outpatient service of First People's Hospital, Yunnan Province and in-patient department patient are as being tried the object of observation, and test group 100 examples wherein are to matched group 100 examples.Male's 46 examples, women's 54 examples in the test group, the oldest 65 years old, minimum 21 years old, average 44.38 years old, the course of disease was the longest 10 years, and was the shortest 0.08, average 1.804 years.Male's 58 examples in the matched group, women's 42 examples, the oldest 65 years old, minimum 21 years old, average 44.65 years old, the course of disease was the longest 10 years, and was the shortest 0.08, average 1.966 years.Details see Table 8.
Table 8 sex, age, course of disease table
The sex age
Example
Group～～～～～～～～～～＞
The number men and women
30 40 50 60 65 1 2 3 4 5 5
Test 100 46 54 13 32 21 24 10 61 13 10 466
Contrast 100 58 42 15 20 32 22 11 59 10 10 786
X
2＝2.88 X
2＝5.32 X
2＝1.52
P＞0.05 P＞0.05 P＞0.05
Learn by statistics and handle, P＞0.05 illustrates two groups of cases there was no significant difference aspect sex, age, the course of disease, has comparability.
Three, case is selected and diagnostic criteria:
(1) diagnostic criteria
1, tcm diagnosis standard: (1) defecation time prolongs, between each defecation every more than 72 hours.(2) just matter is dry and hard, very then as the sheep dung, or agglomerate, and defecation effort, or discharge difficult person, or abdominal distention or and xerostomia, halitosis, oliguria with reddish urine, vexed uneasiness, red tongue, dry, rough and yellow fur, slippery and rapid pulse are arranged.
2, Western medicine diagnose standard: press the functional constipation diagnostic criteria and carry out.
3, differential diagnosis in tcm standard: prescription and function according to this medicine cure mainly the constipation (functional constipation card) that is applicable to differential diagnosis in tcm.Functional constipation card: constipation with dry stool, difficult defecation, very then anal fissure have blood in stool, abdominal distention and pain, bitter taste xerostomia, oliguria with reddish urine, or with halitosis, gingival swelling and pain, red tongue, yellow fur, slippery and rapid pulse.
(2) case choice criteria
1, includes the case standard in: meet the functional constipation course of disease more than January and to meet differential diagnosis in tcm be that functional constipation card person can include the test case in.
2, get rid of or reject the case standard: (1) has confirmed rectum, colon organic disease such as tumor, clone disease, polyp of colon, tuberculosis of intestine, ulcerative colitis on inspection, is got rid of or rejects.(2) gestation or women breast-feeding their children to this medicine allergy sufferers, are got rid of under-18s or over-65s person the age.(3) merge serious primary disease such as cardiovascular, liver, kidney or hemopoietic system and psychotic, got rid of.(4) all standards of including in that do not meet are mismatched the observer; Not medication in accordance with regulations, can't judge that curative effect or data are not congruent and affect the treatment and safety judgement person, be got rid of or reject.
Four, observation index
(1) safety is observed: (1), general health check-up project: before the treatment and the ordinary circumstance during the treatment and heart rate, pulse, blood pressure.(2), routine blood test, test group do 30 examples, stool routine examination is done entirely.(3), liver, kidney function test test group are done 30 examples.
(2) health giving quality is observed: (1), infrequent defecation time, just effort situation, halitosis, gingival swelling and pain etc. when matter, defecation.(2), stool routine examination.
(3) curative effect determinate standard
1, clinical recovery: stool is normal or return to the preceding custom level of disease, and other double disease all disappears.
2, produce effects: constipation obviously improves, blanking time and just matter near normal; Or stool is dried slightly, and the infrequent defecation time, other symptom is most of to disappear in 72 hours.
3, effective: the infrequent defecation time shortens 1 day before the treatment, or the just dry and hard improvement of matter, and other double disease is all taken a favorable turn.
4, invalid: constipation and other double disease all do not have and improve or anti-aggravation person.
Five, clinical implementation scheme
1, verification method: adopt single at random blind method to establish test group and matched group.Test group 100 examples, matched group 100 examples are carried out in two tame hospitals respectively, adopt outpatient service and inpatient's combination.
2, medicament selection: test group capsule of the present invention.The MARENJIAONANG that matched group is produced with the Hunan Yueyang pharmaceutical factory of traditional Chinese medicine.
3, usage, consumption, the course of treatment: capsule of the present invention: three times on the one, one time 2, oral, eliminating cold for resuscitation water send down, three days is a course of treatment, must not add during the treatment with similar medicine and Therapeutic Method.MARENJIAONANG: three times on the one, one time 2, oral, eliminating cold for resuscitation water send down, three days is a course of treatment, must not add during the treatment with similar medicine and Therapeutic Method.
4, the observation of untoward reaction
Should tightly observe general or locality untoward reaction and degree, in case active treatment occurs answering and make itemized record, but termination test when serious.Should tightly observe blood, stool routine examination and liver, renal function.
Six, result of the test
(1) total effects: see Table 9.
Table 9 total effects is observed table example (%)
Group example number recovery from illness produce effects enabledisable total effective rate P value
Test group 100 22 37 36 5 95.00 X
2=2.88
Matched group 100 18 30 43 9 91.00 P＞0.05
Learn by statistics and handle, P＞0.05, two group curative effect there was no significant difference, but from total effective rate, test group (95%) is higher than matched group (91%).
(2) cardinal symptom is observed: see Table 10.
Table 10 observation of symptoms table example (%)
Effectively total
Symptom group example number recovery from illness produce effects enabledisable P value
Rate
Stool
Test group 100 33 28 36 3 97.00 X
2=4.68
At interval
Time
Matched group 100 25 23 44 8 92.00 P＞0.05
Stool
Test group 99 17 30 46 6 93.94 X
2=2.149
Character
Matched group 100 15 25 49 11 89.00 P＞0.05
X
2＝1.052
Abdominal distention test group 93 20 25 35 13 86.02
8
Bitterly
Matched group 95 17 22 40 16 83.16 P＞0.05
Xerostomia
Test group 95 19 24 41 11 88.42 X
2=3.948
Halitosis
Matched group 93 14 19 40 20 78.49 P＞0.05
X
2＝3.322
Gingiva test group 57 18 16 20 3 94.74
8
Swell and ache
Matched group 61 15 12 27 7 88.52 P＞0.05
X
2＝4.452
Urine test group 90 19 20 38 13 85.56
8
Situation
Matched group 86 17 12 35 22 74.42 P＞0.05
X
2＝4.612
Anal fissure test group 60 20 9 25 6 90.00
5
Have blood in stool
Matched group 65 16 5 31 13 80.00 P＞0.05
Learn by statistics and handle, be P＞0.05, two group cardinal symptom curative effect there was no significant difference, but observe from total effectively north, test group is higher than matched group.
(3) tongue arteries and veins, stool routine examination observation of curative effect: see Table 11.
Learn to handle by statistics, two groups in the change of body of the tongue, tongue fur, be P＞0.05, there was no significant difference is described, two groups of therapeutic equivalences.There is significant difference stool routine examination and pulse condition observed result P＜0.05, illustrate that test group improves the aspect to stool routine examination and pulse condition and be better than matched group.
(4) toxic and side effects is observed
In the 100 capsular patients of example clothes the present invention, do 30 example treatment front and back livers, renal function, blood routine examination at random, all in normal range, illustrate that capsule of the present invention does not have obvious harmful effect to liver, renal function and routine blood test, have 1 example stomachache to occur in the test group, loose stool appears in 1 example, but can tolerate, after continuing to take medicine, do not see and increase the weight of that the observation that do not affect the treatment is after finishing the course of treatment, transference cure, all the other
Tangible untoward reaction does not appear in 98 routine patients.
Table 11 tongue arteries and veins, stool routine examination curative effect table
After treating before treating
Project group example number P value
Normal unusual normal unusual
X
2＝0.874
Test group 100 6 94 46 54
2
Body of the tongue
Matched group 100 8 92 41 59 P＞0.05
X
2＝0.054
Test group 100 3 97 34 66
9
Tongue fur
Matched group 100 14 86 43 57 P＞0.05
X
2＝5.626
Test group 100 0 100 43 57
4
Pulse condition
Matched group 100 0 100 27 73 P＞0.05
X
2＝9.091
Test group 100 77 23 96 4
2
Stool Rt
Matched group 100 75 25 85 15 P＞0.05
Seven, discuss
1, takes the clinical observation of " MARENJIAONANG " (matched group) and prove by 100 routine patients being taken capsule of the present invention (test group) and 100 examples, test group and matched group total effects are learned processing by statistics, P＞0.05, not having significantly must difference, the curative effect basically identical is described, but observe from total effective rate, test group (95%) is higher than matched group (91%).
2, from the observation of curative effect of cardinal symptom, learn by statistics and handle, be P＞0.05, there was no significant difference illustrates the curative effect basically identical, but observes from total effective rate, and test group is better than matched group.
3, observe from tongue arteries and veins, stool routine examination, two groups in the change of body of the tongue, tongue fur, be P＞0.05, there was no significant difference is described, two groups of improvement situation basically identicals to body of the tongue, tongue fur.Stool routine examination and pulse condition are observed, and there is significant difference P＜0.05, illustrates that test group is better than matched group to the curative effect of stool routine examination and pulse condition.
4, take among the capsular patient of the present invention in 100 examples, do 30 example treatment front and back livers, renal function and blood routine examination at random,, illustrate that capsule of the present invention does not have obvious harmful effect to liver, renal function and routine blood test all in normal range.Have 1 example stomachache to occur in the test group, loose stool appears in 1 example, but can tolerate, after the continuation medication, do not see and increase the weight of, the observation that do not affect the treatment, finish drug withdrawal the course of treatment after, transference cure, tangible untoward reaction does not appear in all the other 98 routine patients.
Eight, conclusion
The present invention has removing damp-heat, rushes down the effect of turbid relieving constipation, toxin expelling.Through clinical trial, confirm that this medication effect is definite, taking convenience has no side effect, and is the good medicine of treatment constipation, halitosis, gingival swelling and pain.
Claims (3)
1, a kind of medicine for the treatment of constipation, halitosis, gingival swelling and pain is characterized in that being made by the raw material of following weight portion:
Radix Et Rhizoma Rhei 100-120 part Fructus Aurantii Immaturus 100-110 part
Herba Artemisiae Scopariae 100-120 part Radix Angelicae Sinensis 70-85 part
Cortex Moutan 50-60 part Radix Gentianae Macrophyllae 100-120 part
Herba Equiseti Hiemalis 100-120 part Spica Prunellae 100-120 part.
2, medicine according to claim 1 is characterized in that adopting processing method of the prior art to make, and after soon raw material was cleaned, dried, powder became fine powder, mix homogeneously; Perhaps raw material is decocted with water for several times, collecting decoction filters, and filtrate is condensed into thick paste, and dry, pulverizing makes the acceptable preparation product.
3, medicine according to claim 1 is characterized in that allocating medical accessory again into described prescription promptly can be made into pharmaceutically acceptable any dosage form.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200310121022 CN1261121C (en) | 2003-12-30 | 2003-12-30 | Medicine for treating constipation, halitosis and gum swelling |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200310121022 CN1261121C (en) | 2003-12-30 | 2003-12-30 | Medicine for treating constipation, halitosis and gum swelling |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1634193A true CN1634193A (en) | 2005-07-06 |
| CN1261121C CN1261121C (en) | 2006-06-28 |
Family
ID=34844015
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200310121022 Expired - Lifetime CN1261121C (en) | 2003-12-30 | 2003-12-30 | Medicine for treating constipation, halitosis and gum swelling |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1261121C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117298184A (en) * | 2023-11-07 | 2023-12-29 | 云南永孜堂制药有限公司 | Composition for treating constipation and halitosis, and preparation method and application thereof |
-
2003
- 2003-12-30 CN CN 200310121022 patent/CN1261121C/en not_active Expired - Lifetime
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117298184A (en) * | 2023-11-07 | 2023-12-29 | 云南永孜堂制药有限公司 | Composition for treating constipation and halitosis, and preparation method and application thereof |
| CN117298184B (en) * | 2023-11-07 | 2024-02-20 | 云南永孜堂制药有限公司 | Composition for treating constipation and halitosis, and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1261121C (en) | 2006-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1723966A (en) | Compound traditional Chinese medicine for treating fracture and injury, prepn. method and use thereof | |
| CN1457829A (en) | Chinese medicine composition for curing chronic atrophic sastritis and its preparing method and quality control method | |
| CN1733186A (en) | Externally used medicine for curing acute or chronic soft tissue injury and process for preparing the same | |
| CN1762967A (en) | Enoxolone derivative, preparation method and uses | |
| CN1663597A (en) | Qi-invigorating, blood-nourishing medicinal composition and its preparing method | |
| CN1709376A (en) | Compound Chinese medicine formulation for treating qi stagnation epigastralgia, and its preparing method | |
| CN1245189C (en) | Composition for strengthening body resistance and restoring and function, strengthening spleen and kidney, relieving metal stress and promoting blood circulation to remove blood stasis | |
| CN1203872C (en) | Medicine for curing chronic colitis | |
| CN1876099A (en) | Cough-stopping granule with honeysuckle flower and bulbus fritilariae | |
| CN1559495A (en) | Deer's fetus granular Chinese madicinal preparation and its production technology | |
| CN1232267C (en) | Compound plant medicine and its application | |
| CN1297290C (en) | Medicinal composition for treating coronary heart disease and stenocardia and its preparation method | |
| CN1314418C (en) | Medicine for clearing away lung-heat, eliminating phaegn, reliveing cough and asthma and its preparing method | |
| CN1923270A (en) | Medicine for treating benign prostate hyperplasia and method of prepn. of the same | |
| CN1634193A (en) | Medicine for treating constipation, halitosis and gum swelling | |
| CN1803162A (en) | Rhinological disease-treating pharmaceutical compositions and its preparing method | |
| CN1868502A (en) | Medicine composition used for treating rheumatoid arthritis, and its prepn. method | |
| CN1323692C (en) | Pharmaceutical composition for treating lumbago due to kidney-asthenia and its preparing process | |
| CN1602886A (en) | Pharmaceutical compositions and its application | |
| CN1264537C (en) | Capsule | |
| CN1650903A (en) | Method of extracting roice clearing medicament from effective component in natural plant Chinese medicine | |
| CN1990022A (en) | Traditional Chinese medicine composition, its preparation and quality controlling means | |
| CN1724013A (en) | Traditional Chinese medicinal prepn. for treating obstruction of qi in the chest | |
| CN1179735C (en) | Litholytic medicine for treating hepatolith and preparation process thereof | |
| CN1602945A (en) | Rhinitis treating soft medicinal capsule and preparation process thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Kunming Qunfang Pharmaceutical Co., Ltd. Assignor: Zhang Qiongfang Contract fulfillment period: 2009.8.11 to 2023.12.29 Contract record no.: 2009530000007 Denomination of invention: Medicine for treating constipation, halitosis and gum swelling Granted publication date: 20060628 License type: Exclusive license Record date: 20090817 |
|
| LIC | Patent licence contract for exploitation submitted for record |
Free format text: EXCLUSIVE LICENSE; TIME LIMIT OF IMPLEMENTING CONTACT: 2009.8.11 TO 2023.12.29; CHANGE OF CONTRACT Name of requester: KUMING QUNFANG MEDICINE CO., LTD. Effective date: 20090817 |
|
| ASS | Succession or assignment of patent right |
Owner name: YUNNAN YONGZITANG PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: ZHANG QIONGFANG Effective date: 20130726 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 650033 KUNMING, YUNNAN PROVINCE TO: 657000 ZHAOTONG, YUNNAN PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20130726 Address after: 657000 Industrial Zone (railway station connecting line), Zhaoyang District, Yunnan, Zhaotong Patentee after: YUNNAN YONGZITANG PHARMACEUTICAL Co.,Ltd. Address before: Jinding Yunnan science and Technology Park 650033 city of Kunming province Kunming Qunfang Pharmaceutical Co. Ltd. Patentee before: Zhang Qiongfang |
|
| CX01 | Expiry of patent term |
Granted publication date: 20060628 |
|
| CX01 | Expiry of patent term |